Federica Pericle

Federica Pericle, PhD, MBA, was recently the President and CEO of Agilvax, Inc., a biotechnology company developing novel cancer therapies and vaccines for infection diseases. She was responsible of establishing company structure, finance, R&D, legal, board composition, IP and recruitment of KOLs. She raised over $10M in Series A and develop the lead cancer vaccine from inception to pre-IND stage. Prior to Agilvax she was the co-founder and COO of SeneXta Therapeutics, a clinical stage company developing treatments for CNS disorders. Dr. Pericle also served as a scientific advisor for Agennix, Inc. a biopharmaceutical company focused on developing protein-based drugs for oncology. She also worked as Senior Scientist at the National Cancer Institute (NCI) and Moffitt Cancer Center. Dr. Pericle led the development of five product candidates into clinical trials for the treatment of cancer/CNS, published over 50 scientific articles and co-authored five patents in the field of cancer. She received her Ph.D. in Biological Sciences from the University of Turin in Italy and has a specialization in Immunology/Cancer Immunotherapy from the University of South Florida and the University of Turin. She also holds an MBA from Texas A&M University.